The European Medicines Agency has awarded Janssen and MeiraGTx priority medicines (PRIME) designation for the gene therapy they are co-developing to treat the most severe form of retinitis pigmentosa.
AAV-RPGR, for the treatment of x-linked retinitis pigmentosa (XLRP), is the latest investigational product to win a place on the...






